Bioleaders Corporation (142760) — Capital Reinvestment Ratio
Latest as of September 2024:
21.04x
Bioleaders Corporation (142760) has a Capital Reinvestment Ratio of 21.04x as of September 2024, meaning it reinvests 21% of its operating cash flow (₩49.56 Million) in capital expenditures (₩1.04 Billion). See cash generation quality of Bioleaders Corporation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
21.04x
Capex / Operating Cash Flow
Operating Cash Flow
₩49.56 Million
KRW
Capital Expenditures
₩1.04 Billion
KRW
Data as of
Sep 2024
Most recent filing
Bioleaders Corporation Capital Reinvestment Ratio (2023–2023)
This chart tracks Bioleaders Corporation's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Bioleaders Corporation (2023–2023)
Year-by-year Capital Reinvestment Ratio for Bioleaders Corporation from 2023 to 2023. For live market cap and broader valuation context, see Bioleaders Corporation (142760) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.06x | ₩6.18 Billion | ₩378.81 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow